ZK-Epo Given With Carboplatin in Patients With Recurrent Ovarian Cancer

Completed · Phase 2

Conditions studied: Ovarian Neoplasms

In brief

The purpose of this study is to evaluate whether treatment with a new drug called ZK-Epothilone (ZK-Epo) given with carboplatin in patients with recurrent ovarian cancer, who previously have had a good response with cisplatin or carboplatin, is safe and helps to decrease or stop tumor growth.

Key facts

Study ID

NCT00325351

Run by

Bayer

People needed

45

Starts

2006-08-24

Expected to finish

2009-03-25

Last updated by the study team

2021-04-08

Who can join

Age: 18 and older. Sex: female. Healthy volunteers: not accepted.

Where it is running

• Study site — Tucson, Arizona, United States
• Study site — Little Rock, Arkansas, United States
• Study site — Bakersfield, California, United States
• Study site — La Jolla, California, United States
• Study site — San Diego, California, United States
• Study site — Savannah, Georgia, United States
• Study site — South Bend, Indiana, United States
• Study site — Baltimore, Maryland, United States
• Study site — Albuquerque, New Mexico, United States
• Study site — Winston-Salem, North Carolina, United States
• Study site — Cleveland, Ohio, United States
• Study site — Oklahoma City, Oklahoma, United States
• Study site — Knoxville, Tennessee, United States
• Study site — Roanoke, Virginia, United States
• Study site — Calgary, Alberta, Canada
• Study site — Toronto, Ontario, Canada

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.